The historical rank and industry rank for Elicio Therapeutics's Equity-to-Asset or its related term are showing as below:
ELTX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.03 Med: -3.95 Max: 0.42
Current: 0.42
During the past 5 years, the highest Equity to Asset Ratio of Elicio Therapeutics was 0.42. The lowest was -5.03. And the median was -3.95.
ELTX's Equity-to-Asset is ranked worse than 69.91% of 1562
companies
in the Biotechnology industry
Industry Median: 0.67
vs ELTX: 0.42
Elicio Therapeutics Equity-to-Asset Historical Data
The historical data trend for Elicio Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Elicio Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Elicio Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's Equity-to-Asset falls into.
Elicio Therapeutics Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Elicio Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Elicio Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Elicio Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Elicio Therapeutics (Elicio Therapeutics) Business Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELTX has been successfully added to your 